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ABSTRACT
Rutin is a flavonoid glycoside that has shown wide range of pharmacological applications with
various beneficial medical effects. Rutin is poorly soluble in water and could limit its absorption
from the gastrointestinal tract. The aim of this project was to develop and validate a simple UV
analytical method for the evaluation of Rutin release from tablet dosage form. The method was developed by testing solubility of Rutin in different concentrations of sodium lauryl sulfate. The dissolution method was then validated in accordance with international guidelines. The results showed
that the best dissolution was achieved in phosphate buffer pH 6.8 containing 3% SLS. The percent
released was almost 100% after 55 minutes. The developed method was found to be linear, precise
and accurate in the range (0.04-0.1mg/ml). The analytical method was also found to be selective for
Rutin. In conclusion we successfully developed a dissolution method that is easy and feasible. The
validated analytical dissolution method could be used by quality control labs and could be adopted
by the official international pharmacopeias.
Keywords: Rutin, Dissolution, Validation, Tablets.
INTRODUCTION
Rutin
is
a
yellow
crystalline
rhamnoglucoside of the flavonoid quercetin,
it is very slightly soluble in water (1); each
12.5 mg of Rutin is soluble in 100 ml of water (2-4). The chemical formula of Rutin is
C27H30O16.3H2O and its chemical structure is
shown in Figure 1.

3.H2O
Figure (1): Chemical structure of Rutin.
Rutin is abundantly found and distributed in plants such as in buckwheat and various
fruits (5, 6). Rutin is considered a non-toxic
molecule and has advantage over other flavonoids as it behaves as pro-oxidant agent
and catalyzes oxygen production([6). The
main disadvantage of the molecule is its

poor solubility in aqueous media, explaining
its poor oral or topical bioavailability and
being a drawback to its conversion in adequate dosage forms(7).
Rutin proved to have many pharmacological properties such as antitumor, myocardial protective, antihypertensive effects, and
has been used in the treatment of peripheral
vascular diseases because of its vascularprotective properties (8, 9).
Dissolution testing is used mainly in the
development stage of drug products to guide
development of new formulations, to assist in
proper selection of excipients and to optimize
the manufacturing process for optimization
of the therapeutic effectiveness, stability assessment, and in quality control purposes in
order to ensure uniformity between production lots (10). Dissolution of the active pharmaceutical ingredient (API) is affected by
several factors such as the medium in which
the drug is being dissolved, the temperature
of the medium, the dissolution apparatus and
the affinity for the solid particles for the dissolution medium. In the development of a
dissolution procedure these components must
be properly chosen and developed to provide
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a method that is accurate, precise and reproducible in the laboratory (11-13).
Developing dissolution test methods for
poorly water-soluble drug products has been
an important task to formulation scientists
and is of particular importance, where the
absorption is dissolution-rate limited (BCS
class II drugs). At the same time, development of a dissolution method for this group
of drugs is very challenging; difficulties are
usually encountered in selecting a dissolution
medium of acceptable volume and composition as well as a good discrimination power.
General strategies to enhance their dissolution patterns rely upon either optimizing the
dissolution medium pH, or adding
solubilizers such as surfactants (14, 15). The
types of surfactants that were used in the
dosage form to increase the dissolution include anionic, cationic and nonionic forms.
Moreover, surfactants influence tablet disintegration rates, producing a finer dispersion
of disintegrated particles with a correspondingly larger surface area for drug dissolution
(14, 16).
The objective of this study is to develop
a simple and feasible dissolution method to
quantify dissolved Rutin of commercially
available Rutin tablet. The solubility of Rutin
will be enhanced using anionic surfactant.
The percentage of the surfactant and dissolution medium will be optimized to have the
best Rutin solubility. The method will then
be validated to demonstrate that the test procedure is suitable for its intended purpose.
Validation of a dissolution method will take
into account the validation parameters including: specificity, accuracy, linearity, precision and robustness. The validation process
must follow the ICH guidelines (13, 17, 18).
MATERIALS AND METHODS

Phosphate, Sodium hydroxide, Sodium Acetate, Glacial Acetic Acid and HCl 37% solution. Freshly deionised water was used
throughout the study. Product Solgar tablets
containing 500mg Rutin per tablet was purchased from local community pharmacy. Inhouse prepared Product Rutin Tablets, containing 500mg of Rutin were prepared in our
research laboratories, the following excipients were used in the tablet formulation: Colloidal Silicon Dioxide, Croscarmellose Sodium and Microcrystalline Cellulose. All these
tablet excipients were given as a gift from
Jerusalem
Pharmaceuticals
CompanyPalestine.
Instrumentation
The following instruments were used in
this research project: UV/visible Spectrophotometer (JENWAY-Model7315) using 10mm
quartz cells was used for all absorbance
measurements. Six-station Paddle Dissolution Tester (HSIANGTAI, DT-6) in accordance with USP general methods, pH meter
(JENWAY -3510), hotplate stirrer (LabTech,
ES35A), analytical balance (Nevada Weighing, Radwag- AS 220.R2).
Solutions preparation
All solutions used throughout the research project; phosphate buffer (pH 6.8),
0.1N HCl and acetate buffer pH 4.5. were
prepared according to directions in USP
monograph (19).
Dissolution development procedure
Determination of λ max absorption
At first the λ max absorption was determined using UV-Vis spectrophotometer by
scanning Rutin in the range of 200nm800nm.

Materials, Chemicals and Reagents

Determination of saturation solubility and
sink conditions

Rutin trihydrate powder (99%) was purchased form (Sigma Aldrich-Germany), sodium lauryl sulfate (SLS) surfactant was purchased form (Sigma Aldrich- USA). Potassium dihydrogen phosphate was purchased
form (Alfa Aesar- Germany). The other entire reagents used were of analytical grade
and were purchased form reliable resources
these reagents include: Sodium Dihydrogen

In the early stages of dissolution method
development, it is of important to characterize the medium to be chosen properly in order to evaluate the performance of the dosage
form. Solubility data were used as a basis for
the selection of a dissolution medium for
Rutin. The saturation solubility of Rutin was
determined at 37° in different media and expressed as mg/mL. The term sink conditions
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(20) is defined as the volume of medium at
least three times greater than that required to
form a saturated solution of drug substance.
Sink conditions were determined in the following media: 0.1N HCl, pH 4.5 acetate
buffer, pH 6.8 phosphate buffer, pH 6.8
phosphate buffer containing 3.0% of Sodium
Lauryl Sulphate (SLS) and water containing
different concentrations of SLS (i.e., 0.5%,
1.0%, 1.5%, 2.0%, 2.5%, 3.0%, 4.0%, and
5.0%). Experiments were conducted in triplicate. Excess amount of Rutin was added in
each medium in a 10-ml screw-capped vial.
The vials were shaken continuously in a
shaker for 24 h at 37°. The solutions were
kept aside at the same temperature for 4 h
until equilibrium was achieved. The equilibrated samples were immediately filtered
through 0.45 µm polyamide filter and analyzed spectrophotometrically at 360 nm after
appropriate dilutions with medium.
Dissolution release profile comparison of
formulated Rutin
The dissolution tests were carried out on
both a commercial Rutin 500mg tablet from
Solgar, and in-house prepared Rutin 500mg
Tablets by employing USP Apparatus II at
37±0,5°. Each dissolution test was performed
in triplicate. In each dissolution testing a
paddle speed of 100 rpm, different dissolution media (water, phosphate buffer pH 6.8
and phosphate buffer pH 6.8 containing 3.0%
SLS) with 900ml of were used.
Sampling aliquots of 10 ml were
withdrawn from each vessel and the
same volume of the dissolution medium
was replaced to maintain a constant total
volume of 900 ml. The times schedule of
sampling were every 5 minutes for the
first hour then every 10 minutes for the
next half hour and the last sample was
collected after
30 minutes. After the
end of each test time, sample aliquots
were filtered through 0.45µm polyamide
membrane filter, diluted with respective
dissolution medium, when necessary and
analyzed spectrophotometrically.
Method Validation
In this present research work, the developed UV spectrophotometric dissolution
method was validated as per ICH guide-

lines(17). Different validation parameters
were examined in this dissolution development method these validation parameters include: specificity, linearity, range, accuracy,
and robustness.
The specificity parameters of the dissolution method were performed by examining
the absorbance of the placebo solution which
consisted of a solution of phosphate buffer
pH 6.8 with 3% SLS and all the excipients of
the formulated Rutin. The placebo concentrations were determined based on the Handbook of Pharmaceutical Excipients and calculated for an average weight of Rutin tablet
content (21). The excipients per Rutin tablet
were as follows: aerosol (2mg), AcDiSol®
(4mg), MCC(72mg) and magnesium stearate
(2mg).
Linearity was tested across a range of 5
concentrations and was evaluated from the
linearity plot by examining the square of the
correlation coefficient (R2).The linearity of
our developed method was examined by preparing a series of Rutin standard solutions
(0.04,0.05, 0.06, 0.08, and 0.1 mg/ml).The
absorbance of the tested solutions was plotted
against their concentration. The regression
line equation and the R2 value were examined to check the linearity of the method.
The accuracy was performed by measuring the recovery of known amounts of Rutin
in the dissolution vessels. Three concentrations (20%, 100% and 120) of the theoretical
Rutin concentration were spiked and the
measurements were done in triplicate. The
average recovery percentage was calculated.
Precision of the method was determined
by measuring the repeatability, intraday precision and inter-day precision. The analytical
solution of three concentration levels (20%,
100% and 120%) was measured six times on
three different days. The precision of the
method was determined by measuring the
repeatability. (intra-day precision) in the
same day and the intermediate precision (inter-day precision) in two different days, all
are expressed as RSD (%). The precision of
the data between days was demonstrated by
ANOVA statistical testing(22).
The robustness of the analytical procedure is the measure of its capacity to remain
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method was examined by calculating the
%RSD and applying an ANOVA statistical
test.

unaffected by small deliberate variations in
parameters internal to the procedure. We intentionally varied three parameters: the pH of
the buffer, the absorbance, and analyst. The
phosphate buffer pH 6.8 was intentionally
varied by ±0.2 pH units. Rutin solution in
phosphate buffer 6.8 containing 3% SLS was
measured at three different wavelengths:
358nm, 360nm, and 362nm. Lastly the absorbance of Rutin solution was measured by
two different analysts. The robustness of the

RESULTS
Dissolution method development
The UV-Vis spectra of the Rutin solution revealed two absorption maxima, one
was in the UV region (255nm) and the other
was in the visible region (360nm) (Figure 2).
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Figure (2): Absorption spectrum of Rutin 2% aq. Solution in the range of 200-500 nm.
phate buffer containing 3% SLS in which the
The solubility results of Rutin in differconcentration of the dissolved Rutin was
ent proposed dissolution media are summa1.690mg/ml.
rized in Table 1. The data demonstrated that
the sink condition is provided by using PhosTable (1): Solubility results of Rutin in different proposed dissolution media.
Medium
Water
Water containing 0.5% SLS
Water containing 1.0% SLS
Water containing 1.5% SLS
Water containing 2.0% SLS
Water containing 2.5% SLS
Water containing 3.0% SLS
Water containing 4.0% SLS
Water containing 5.0% SLS
0.1N HCl containing 3.0% SLS
Acetate Buffer pH 4.5 containing 3.0% SLS
Phosphate Buffer pH 6.8 containing 3.0% SLS
Phosphate Buffer pH 6.8 containing 3.0% SLS

Solubility of
Rutin (mg/ml)
0.16
0.336
0.047
0.636
0.770
0.936
1.635
1.539
1.619
0.720
1.080
1.200
1.690

Sink condition (solubility
>1.667mg/ml)*
No
No
No
No
No
No
Almost
Almost
Almost
No
No
No
Yes

* Calculated from 500mg/900 ml x 3 = 1.667mg/ml.

Dissolution release profiles comparison
The dissolution profile results showed a
significant difference in the dissolution pro-

file of Rutin 500mg (in house prepared) tablet in the three dissolution media namely:
Distilled water, Phosphate buffer pH 6.8, and
3% SLS in phosphate buffer pH 6.8 media.
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The results showed that the best dissolution
was achieved in phosphate buffer pH 6.8
containing 3% SLS because the sink condition was provided. The percent released was

almost 100% after 55 minutes, while in water
alone and in the buffer alone did not exceed
28.06, and 37.82 % respectively after two
hours (Figure 3).
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Figure (3): Dissolution profile of Rutin tablets in different dissolution media.

Dissolution percentage

The dissolution comparison between inhouse formulated Rutin tablets 500mg and
Rutin® 500 mg tablet-Solgar showed a
slightly higher dissolution rate for the

marketed Rutin tablet of Solgar. The dissolution profiles of the two products are shown in
Figure 4.
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Figure (4): Comparison between in-house formulated tablet and Solgar Rutin ® tablet.
absorption spectrum of dissolution medium
shows no absorbance peak at 360 nm. These
results clearly show that at this wavelength
there are no interferences from the excipients. The overlay of absorption scans of the
tablet excipients and Rutin are shown in Figure 5.

Validation
The selectivity of the method was examined by testing the absorbance of the tablet
excipients and the Rutin solution separately.
The results show that the developed method
was selective. The
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Figure (5): Overlay absorption spectrum of dissolution medium of excipients and Rutin.
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Linearity and range results showed that
the calibration curve equation was (y =
21.844x + 0.0457) and square of the correlation coefficient (R2) was = 0.9969
2.5

y = 21.844x + 0.0457
R² = 0.9969

2
absorpance

(Figure 6). The results clearly demonstrate
that the method is linear in the tested dissolution range of (0.04-0.1mg/ml).
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Figure (6): Linearity curve of Rutin standards in phosphate buffer pH 6.8 containing 3% SLS at
360 nm.
Table (3): Inter-day and intra-day precision
The results showed good recovery perassay of Rutin tablet.
centage (97.8 -0.98). This result clearly
Perdemonstrates the accuracy of the developed
% RSD
centage
Pmethod. The calculated concentration and
st
th
th
assay
value
1
day
5
day
6
day
the percentage recovery are shown in Table
level
2.
Table (2): Percentage recovery of Rutin at
three concentration levels.
Concentration %
20%
100%
120%

% recovery
98%
97.8%
97%

The precision results showed %RSD in
the range of 0.5-3.11 among the samples prepared on the same day under the same conditions. The detailed results of % RSD for each
recovery level is shown in Table 3. The table
also shows the results of the ANOVA test
which shows no significant difference between the readings on different days. The
ANOVA test showed no significant difference between the results of the three tests
done on the first , fifth and sixth day. However, the reading of 100% was an exceptional
case; this could be due to low number of tested samples.

20%

0.902967

0.232028

1.16206

0.571

100%

0.578643

2.4264

3.110845

0.04

120

2.043047

0.96432

1.812164

0.571

Our developed method proved to be robust; the results showed that intentional variability of the measuring wave length, the media pH and the analyst did not considerably
affect the consistency of results (Table 4).
The results show that there is no variability
among the results; none of the %RDS exceeded 5 and none of the P values were >
0.05.
Table(4): Robustness results at different variable parameters.
Parameters

%RSD

P value

Different Analysts

3.08

0.51

Variation in pH ±2

5

0.07

Variation in the wavelength 360nm±2

4.7

0.06524
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DISCUSSION
In this research project a UVspectrophotometric dissolution method was
developed to analyze very slightly soluble
Rutin in tablet dosage form. Developing dissolution test methods for poorly watersoluble drug products has been an important
task to formulation scientists and very challenging. The choice of apparatus is based on
the dosage form performance in vitro test
system. The apparatus used in dissolution of
solid dosage form (immediate release, modified release) products are either type 1 or
type 2. In our case we used apparatus type 2
because of its availability in our laboratory.
The method development involved determination of the maximum absorption. Two
λ max were observed one in UV region and
the other was in the visible region. The λ
max absorption of the visible region was selected for the analysis of Rutin. This wavelength was selected to avoid any
possible interference from the excipients
which might absorb in the UV region.
The choice of a medium, like any other
experimental conditions for dissolution testing, should be linked to appropriate physiological characteristics which are similar to
those of the gastrointestinal tract(23). The
most common dissolution medium is dilute
hydrochloric acid, however other media
commonly used include buffers at physiological pH and stimulated gastric or intestinal
fluid(13).In this case, we examined the dissolution of Rutin in three media (hydrochloric
acid, sodium acetate buffer, and phosphate
buffer) in order to see which one was suitable
for dissolving it. The solubility results of the
three media demonstrate that phosphate buffer was the best media for dissolving Rutin
and the acidic media (0.1N HCl) was the
least suitable.
Sodium Lauryl Sulfate (anionic surfactant) has been proven as a reagent of choice
for dissolution studies because it is inexpensive and it possesses good solubilizing capacity at relatively low concentrations. Several
authors reported that SLS could enhance dissolution of poorly soluble drugs above its
critical micelle concentration (14, 24).
In this present research work, the developed UV spectrophotometric dissolution

method was validated as per ICH guidelines.
Different validation parameters were examined in this dissolution development method
these validation parameters include: specificity, linearity, range, accuracy, and robustness. These results clearly show that method
is accurate and linear in the range of 0.040.1mg/ml.The absorbance measurement at
wavelength (360) has no interferences from
the excipients which make the method selective for Rutin. Our developed method proved
to be robust; the intentional variability of the
measuring wave length, the media pH and the
analyst did not considerably affect the consistency of result. This proves that a small
variation of the method conditions do not
affect the result.
The developed method might be adapted
as an official method in an international
pharmacopeia and can be adapted by quality
control labs to analyze Rutin tablets in the
local and international market. Our developed dissolution method will enable herbal
medicine factories to apply this dissolution
method in the quality control of their similar
herbal products.
CONCLUSION
In conclusion we successfully developed
a simple and feasible UV- visible spectrophotometric analytical method to quantify the
dissolution of Rutin tablets. The method used
SLS surfactant in a phosphate buffer pH 6.8
as a dissolution medium to release and solubilize Rutin to about 100%. The method was
further validated in accordance with the international guidelines. The method was found
to be linear, specific, accurate and robust.
This developed method could be used for
quality control labs and could be adopted by
the official international pharmacopeias.
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